Examples of using Vimizim in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
How does Vimizim work?
Other information about Vimizim.
How Vimizim is given?
Other medicines and Vimizim.
How is Vimizim used?
People also translate
Vimizim contains sodium and sorbitol.
Why is Vimizim approved?
Vimizim is a medicine that contains the active substance elosulfase alfa.
If you are treated with Vimizim, you may develop infusion reactions.
Vimizim 1 mg/ml concentrate for solution for infusion elosulfase alfa.
For the full list of all side effects reported with Vimizim, see the package leaflet.
Total amount(ml) Vimizim divided by 5 ml per vial Total number of vials.
The data in Table 2 below describes adversereactions from clinical trials in patients treated with Vimizim.
Vimizim may be started at as young as an age possible and is intended for long term use.
Discuss with your doctor if the benefits of taking Vimizim are greater than the potential risk to your newborn while breast-feeding.
Vimizim has to be diluted with sodium chloride 9 mg/ml(0.9%) solution for infusion using aseptic technique.
In patients< 5 years of age, the overall safety profile of Vimizim at 2 mg/kg/week was consistent with the safety profile of Vimizim observed in older children.
Vimizim should not be mixed with other medicinal products in the same infusion, except for those mentioned below.
The Committee also considered that the safety profile of Vimizim appears manageable and serious side effects are uncommon, but further long-term safety data are to be collected.
Vimizim is indicated for the treatment of mucopolysaccharidosis, type IVA(Morquio A Syndrome, MPS IVA) in patients of all ages.
The majority of patients who received Vimizim during clinical studies were in the paediatric and adolescent age range 5 to 17 years.
Vimizim has been investigated in one main study involving 176 patients with MPS IVA, which compared Vimizim with placebo a dummy treatment.
Treatment with Vimizim should be supervised by a doctor experienced in MPS IVA or similar diseases.
Vimizim contains an enzyme called elosulfase alfa, which belongs to a group of medicines known as enzyme replacement therapies.
Before withdrawing Vimizim from the vial, each vial is visually inspected for particulate matter and discoloration.
Vimizim treatment should be supervised by a physician experienced in the management of patients with MPS IVA or other inherited metabolic diseases.
The safety and efficacy of Vimizim in patients older than 65 years has not been established, and no alternative dosage regimen can be recommended in these patients.
Vimizim must not be used in patients who have experienced life-threatening allergic reactions to elosulfase alfa or any of the other ingredients in Vimizim.
Clinical trials performed with Vimizim assessed the impact of treatment on the systemic manifestations of MPS IVA in various domains including endurance, respiratory function, growth velocity, and mobility, as well as urine KS.
In addition, the company that makes Vimizim must ensure that all healthcare professionals expected to prescribe or use the medicine are provided with educational material, informing them of how the medicine should be used and the risk of severe allergic reactions.